Summary of "Obesity Drugs Enter Their Second Act"

Author: Ruben Dalfovo, Investment Strategist

Date: June 9, 2026

Key Takeaways

• Eli Lilly remains the leader in the obesity drug market, but the focus is shifting beyond just weight loss.
• Demand for Novo Nordisk's Wegovy pill is strong, though concerns about its long-term competitive edge persist.
• Competition is increasingly centered on oral medications, reduced side effects, lower pricing, and broader health benefits.

Market Dynamics

The landscape of obesity drugs is evolving. At the recent American Diabetes Association meeting, it was evident that while Eli Lilly is maintaining its lead, Novo Nordisk is actively responding with new products and strategies. Over the past year, Eli Lilly's stock has risen by approximately 42%, while Novo Nordisk's has fallen by about 47%. AstraZeneca has also seen a 27% increase, bolstered by its growing reputation as a competitor in the obesity market.

Eli Lilly's Innovations

Eli Lilly's growth in the obesity sector is largely driven by its drug Zepbound and the promising retatrutide, a triple agonist that targets multiple biological pathways related to appetite and metabolism. Recent data indicates that patients using the highest dose of retatrutide experienced an average weight loss of 28.3% over 80 weeks, with some achieving over 30%. Additionally, the drug shows potential benefits for related health issues such as sleep apnea and type 2 diabetes, which could enhance its appeal beyond mere weight loss.

Challenges for Novo Nordisk

Despite its historical dominance, Novo Nordisk faces challenges in maintaining its market position. The Wegovy pill has gained significant traction, with over 3 million prescriptions in the U.S. since its launch in January 2026. The convenience of a pill over injections is a key selling point, attracting new patients to the GLP-1 therapy category. Novo is also advancing its pipeline with CagriSema, a combination therapy that has shown promise in reducing both blood sugar and body weight.

Emerging Competitors

The obesity treatment market is expanding, with over 1 billion people affected globally. AstraZeneca is emerging as a notable competitor with its experimental pill, elecoglipron, which has demonstrated weight loss results in trials. Other companies are exploring various approaches, including gentler amylin-based drugs and monthly injections, to capture market share.

Risks to Monitor

Investors should be aware of several risks in the obesity drug market:

• Tolerability: Side effects such as nausea and treatment dropouts can hinder long-term adoption.
• Pricing and Access: The high cost of these medications may limit their accessibility and insurance coverage.
• Competition: New entrants could drive prices down, and setbacks in drug development could alter market dynamics.

Investment Insights

Investors are advised to focus on patient adherence to medications, as sustained use is crucial for value creation. It is also important to differentiate between scientific efficacy and market performance, as strong trial results do not guarantee commercial success. A diverse pipeline of drugs can provide resilience against market fluctuations, and the evolving nature of the obesity treatment landscape suggests that success will depend on a combination of efficacy, safety, and accessibility.

Conclusion

The obesity drug market is maturing, with a shift from simple weight loss metrics to a broader focus on overall health benefits and patient experience. While Eli Lilly currently leads, Novo Nordisk and other competitors are actively innovating, making the landscape dynamic and competitive.